Business operations

12 Months Ended

Mar. 31, 2013

Business operations [Abstract]

Business operations

3.  Business operations:

The Company and its principal operating subsidiaries, which are located primarily in the United States (U.S.) and Europe, manufacture and market ethical pharmaceutical products and other healthcare products.  The Company operates in only one segment.  Sales are primarily in the U.S. and European markets.  The net sales and long-lived assets for the years ended March 31, 2013, 2012 and 2011, are from the Company's or one of its subsidiaries' country of origin, as follows:

(In thousands)	2013				2012				2011
	Net sales		Long-lived assets		Net sales		Long-lived assets		Net sales		Long-lived assets
U.S.	$	2,769,541	$	432,085	$	4,261,976	$	386,427	$	4,126,030	$	292,463
Ireland		60,014		2,759,428		61,747		2,759,069		33,145		763,787
United Kingdom		75,381		26,177		68,825		31,663		53,951		3,975
	$	2,904,936	$	3,217,690	$	4,392,548	$	3,177,159	$	4,213,126	$	1,060,225

Net sales exclude sales between the Company and its subsidiaries.

Net sales by therapeutic class are as follows:

(In thousands)
Years ended March 31,	2013		2012		2011
Central nervous system (CNS)	$	1,997,188	$	3,694,898	$	3,688,764
Cardiovascular		483,733		381,621		311,769
Other		424,015		316,029		212,593
	$	2,904,936	$	4,392,548	$	4,213,126

The Company's CNS franchise consisting of Lexapro®, Namenda®, Savella®, Celexa® and Viibryd® accounted for 69%, 84% and 88% of the Company's net sales for the years ended March 31, 2013, 2012 and 2011, respectively.

The following illustrates net sales to the Company's principal customers:

	2013			2012			2011
McKesson Drug Company		38	%		36	%		37	%
Cardinal Health, Inc.		29	%		30	%		32	%
AmerisourceBergen Corporation		20	%		20	%		20	%